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Abstract
The overarching goal of this review is to examine the current best evidence for assessing bipolar
disorder in children and adolescents and provide a comprehensive, evidence-based approach to
diagnosis. Evidence-based assessment strategies are organized around the “3 Ps” of clinical
assessment: Predict important criteria or developmental trajectories, Prescribe a change in
treatment choice, and inform Process of treating the youth and his/her family. The review
characterizes bipolar disorder in youths - specifically addressing bipolar diagnoses and clinical
subtypes; then provides an actuarial approach to assessment - using prevalence of disorder, risk
factors, and questionnaires; discusses treatment thresholds; and identifies practical measures of
process and outcomes. The clinical tools and risk factors selected for inclusion in this review
represent the best empirical evidence in the literature. By the end of the review, clinicians will
have a framework and set of clinically useful tools with which to effectively make evidence-based
decisions regarding the diagnosis of bipolar disorder in children and adolescents.
There have been radical changes in our scientific understanding and clinical practices
around the diagnosis of bipolar disorder in children and adolescents. Whereas the condition
used to seldom be diagnosed before puberty, there has been a recent surge in rates of
diagnosis such that a large proportion of psychiatrically hospitalized youths now carry
clinical diagnoses of bipolar disorder 1, and there has been a more than 40 fold increase in
rates of diagnoses over a 10-year period 2. There has been debate about whether the increase
in diagnosis is primarily due to a correction of previous under-diagnosis, versus concerns
that it is now overdiagnosed or even a case of “diseasemongering” 3. Discussion has also
focused on whether bipolar disorder in youth is the same illness as in adults, versus
representing a different condition or perhaps a pediatric subtype 4-6. Although the topic is
still portrayed as controversial in the popular media, at this point more than 350 peer-
reviewed publications have investigated different aspects of pediatric bipolar illness 7.
Growing evidence from clinical and epidemiological studies around the world indicates that
bipolar disorder often first manifests in adolescence or earlier 8,9, and many apparent
differences between adult and child presentations appear to be an artifact of definitional
issues and not real variations in clinical presentation 7. Prospective longitudinal studies also
are documenting moderate to high levels of developmental continuity with adult bipolar
disorder 10-12. All lines of evidence strongly indicate that bipolar symptoms in youths are
associated with considerable impairment and warrant clinical attention.
The goal of the present review is to provide a step-by-step, evidence-based approach to the
assessment of bipolar disorder in children and adolescents. The review is organized around
clinical decision-making and then monitoring progress over the course of treatment. The
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review does not discuss the potential merits of all the most commonly used instruments for
psychological, educational, or psychiatric assessment; instead, it concentrates on those tools
that have research supporting their validity with regard to pediatric bipolar disorder. The
majority of the assessment tools routinely used for psychological 13 and psychiatric
evaluation have not been validated for work with pediatric bipolar disorder 14. Rather than
using standardized assessment batteries out of convention or habit, we believe that the
assessment endeavor will perform best when each component is chosen based on its
demonstrated validity and relevance to clinical intervention. Evaluation strategies should
address one of the “3 Ps” of clinical assessment: 1) Predict important criteria or
developmental trajectories, 2) Prescribe a change in treatment choice, or 3) Inform the
Process of treating the patient or family 15. Narrowing assessment batteries down in this
manner has many benefits that include creating a strong link between assessment and
treatment, reducing time and expense by eliminating unnecessary testing, and improving
decisions and treatment outcomes by reducing “information clutter” and providing more
focused information that directly pertains to the individual patient. The 3 Ps provide a rubric
to help navigate the assessment process from establishing risk of pediatric bipolar disorder,
confirming the diagnosis, informing treatment selection, measuring progress and outcome,
and monitoring for relapse prevention.
Definitions: Mood Episodes and Bipolar Spectrum
The diagnostic criteria for mood disorders are unusual in that they require a two-stage
evaluation 16,17. First, the clinician must evaluate the lifetime history of mood episodes, not
just characterizing the current presenting problem. Only after gathering data about the
possible occurrence of each type of potential mood episode over the lifetime can the
clinician proceed to establishing the formal diagnosis. Diagnosing bipolar disorder requires
this complexity, because the presentation of the illness can change dramatically as it
transitions into different episodes.
Mood Episodes
The diagnostic mood episodes include major depressive episodes, dysthymic episodes,
hypomanic symptoms, hypomanic episodes, manic episodes, and mixed episodes. These
categories are not exhaustive in terms of phenomenology. Additional mood presentations are
possible and frequently encountered in clinical practice, including mild depressions, mixed
hypomanias, and periods of mood dysregulation that are too brief or mild to meet current
criteria for an index episode 18. However, the formal diagnosis of mood disorder is anchored
to the index episodes, not the other clinical presentations. It is only after ascertaining both
the present and past lifetime mood episodes that the clinician can diagnose mood disorders
accurately. Table 1 shows how the combination of present and past episodes is often
necessary to make a diagnosis on the bipolar spectrum. Unless the clinician inquires about
past mood history, many cases of bipolar disorder will be misdiagnosed as unipolar
depressive or dysthymic disorders – particularly given that people affected by bipolar
disorders tend to spend more days depressed than manic, and are much more likely to seek
services for depression than mania 19. The situation may be somewhat different with
pediatric bipolar disorder, both because referrals are more often initiated by the parent rather
than the youth in outpatient settings, and because mania and mixed episodes appear to be
more common in younger cohorts and then decrease steadily with age 8,20.
Diagnoses
Bipolar I, often considered the most serious form of bipolar illness, has received the greatest
attention from the research community. As Table 1 makes evident, a bipolar I diagnosis only
requires the presence of one manic or mixed lifetime episode 17. Bipolar II disorder, in
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contrast, requires two distinct mood episodes in order to assign the diagnosis: at least one
major depressive episode and a hypomanic episode. Without systematic assessment for
lifetime hypomanic episodes, bipolar II is very likely to be misdiagnosed as a unipolar
depression 21.
The DSM-IV includes cyclothymic disorder as another condition to be considered in the
bipolar family of disorders. The diagnostic criteria for cyclothymic disorder require long
periods of moderate mood disturbance. The depressive symptoms cannot become too severe,
or else the diagnosis would change to a major depressive episode or bipolar II disorder.
Similarly, the hypomanic symptoms cannot become too extreme; otherwise, if they meet
criteria for a full manic episode, then the diagnosis would change to bipolar I. Cyclothymic
disorder is difficult to distinguish from temperament; indeed, much research in the area has
used rating scales assessing cyclothymic temperament 22. The diagnosis of cyclothymic
disorder is rarely used in clinical practice 23, nor is it tracked in most large epidemiological
studies or clinical research samples 8,10,24,25. However, those studies that have investigated
cyclothymic disorder have found that it is a highly impairing condition that warrants clinical
attention 26-33.
Bipolar “not otherwise specified” (NOS) is a fourth diagnostic option in the bipolar section
of DSM-IV. Bipolar NOS is a residual category, intended to be used when bipolar features
are present, but the clinical presentation does not fit into any of the three above categories.
DSM-IV provides some examples of presentations that would be appropriate to code as
bipolar NOS. These include having recurrent hypomanias without any lifetime history of
manic, mixed, or major depressive episodes 34; having a disturbance in mood but with an
insufficient number of the possible seven B criteria symptoms (e.g., elated mood plus one or
two other symptoms; or irritable mood plus fewer than four other symptoms); or cases
where the duration of the index mood episode is not long enough to satisfy the thresholds
specified for hypomania (four days), or mania or mixed episodes (one week, or else severe
enough to necessitate psychiatric hospitalization). Both the “insufficient number of
symptoms” 12,35,36 and the “insufficient duration” forms of bipolar NOS 26,37 have been
documented in multiple studies in both children and adults. Although the definitions do not
identify identical sets of cases, the cumulative evidence shows that either definition is
associated with considerable chronicity and clinical impairment. If the core feature of
episodic mood disturbance is present, then most evidence suggests that bipolar NOS falls on
the bipolar spectrum. In short, bipolar NOS (a) appears to be at least as prevalent as bipolar I
in epidemiological and clinical samples, (b) has become well established as an impairing
mood disorder, and (c) deserves clinical attention.
There is an important consideration about the potential overlap between bipolar NOS and
cyclothymic disorder. In practice, most practitioners and researchers tend to lump
cyclothymic disorder into the bipolar NOS category. Technically this is a departure from the
official nosologies 16,17, and it adds to the heterogeneity that is found under the rubric of
bipolar NOS. The combination of short durations for mood states combined with long
lengths of episode should trigger careful evaluation of the possibility of a cyclothymic
disorder.
When making any of the bipolar diagnoses, the clinician must rule out the possibility that
the mood symptoms are due to schizophrenia, a general medical condition, or induced by a
substance 16,17. The substance induced exclusion criteria creates the most challenges. Street
drugs that have a strong dopaminergic effect can mimic the symptoms of mania, and
hallucinogens can create symptoms that appear psychotic. A more subtle point is that manic
symptoms secondary to the use of prescription medications, including antidepressant or
stimulant medications, technically lead to diagnoses of “substance induced mania”. The
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literature on psychotropic medications inducing mania is complex 38, but experts agree that
manic symptoms emerging during the course of treatment always justify thorough
evaluation of the possibility of bipolar diagnosis.
Additional Subtypes of Bipolar Disorder
In the pediatric literature, there has been much discussion about changes to criteria for
youths or alternate definitions of bipolar subtypes 6. Leibenluft and colleagues suggested the
term “narrow phenotype” to indicate situations where the manic episode included symptoms
of elated mood or grandiosity, consistent with the research operational definition of bipolar
disorder used by Geller and colleagues 6,39. People often think that the term “narrow”
connotes strict adherence to DSM criteria, but actually the “narrow” definition is more
restrictive than DSM criteria (which would include hypomania or mania with predominantly
irritable mood, so long as there were sufficient numbers of B-criteria symptoms co-
occurring). In manysamples, there is substantial overlap between the cases that would meet
DSM criteria that would also satisfy the narrow definition 37,40. There is also considerably
less research available based on the narrow criteria instead of the DSM criteria 41. At the
other extreme, the term “broad phenotype” has been used so widely and to refer to so many
different things that it has become imprecise to the point of losing clinical utility. Because
the evidence base is much stronger for DSM definitions than any alternate research
definitions and DSM criteria guide clinical practice, the rest of this review will concentrate
on DSM definitions (bipolar I, bipolar II, cyclothymic disorder, and bipolar NOS –
clarifying whenever possible if the NOS specification is due to insufficient symptoms or
insufficient duration).
Course Specifiers: Definitions and Clinical Relevance
Course specifiers have considerable clinical value in the context of bipolar disorder.
Notations such as “bipolar II disorder, current episode depressed” provide important
information about the nature of the illness and change some of the treatment options (i.e.,
prescription of different interventions for unipolar versus bipolar depression). There has
been inconsistency about the use of the terms “cycling” and “rapid cycling.” These are often
used to connote polarity switches. However, the DSM definition of rapid cycling denotes the
occurrence of at least four or more distinct mood episodes (not changes in mood state within
an episode) within the same year. Thus, rapid cycling might be thought of as “rapid
recurrence” or “rapid relapse.” Indeed, when defined as four or more annual episodes, “rapid
cycling” portends to a much more chronic course, higher rates of comorbidity and substance
use, greater treatment refractoriness, and potentially greater risk of suicide. Thus the
phenomenon of “rapid cycling/relapsing” satisfies both the predictive and prescriptive
litmus tests for inclusion in an assessment of bipolar disorder. If the rapid switching between
mood polarities that has been well-described in children is better construed as a mixed
episode rather than multiple episodes; then the terms are being used consistently across the
lifespan, and clinicians can better identify when there is a higher risk of relapse.
How Common Is Pediatric Bipolar Disorder? Baseline Risk and Prevalence
The first question that must be answered is, “How common is pediatric bipolar disorder,
anyway?” At the time most practicing clinicians were trained, the conventional wisdom was
that bipolar disorder affected only adults and perhaps some adolescents; and the vast
majority of training programs still do not provide formal didactics about the assessment or
treatment of pediatric bipolar disorder 42. The prevalence of the disorder is an important
starting point for clinical evaluation.
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The traditional figure has been that bipolar disorder affects 1% of the adult population. This
figure was often based on rates of bipolar I, and excluded all other DSM bipolar diagnoses.
More recent epidemiological studies have found lifetime prevalences of bipolar I and II to
be closer to 3 or 4% 24,25, and bipolar spectrum diagnoses appear to affect from 2.6% to
8.3% or more 36 of the general population (see Goodwin and Jamison for a review of twelve
international studies)8. Unfortunately, epidemiological studies tend not to use strict DSM
criteria for diagnoses, making it difficult to map findings directly onto clinical labels.
Despite the varying definitions, it is clearly evident that (a) the bipolar spectrum is more
common than generally thought, (b) the “soft spectrum” cases occur at least as frequently as
does bipolar I in both community and clinical samples, and (c) the soft spectrum is
associated with both immediate impairment and long term risk of poor outcomes on multiple
measures 10,36,37,43,44.
A major caveat for the clinician is that epidemiological studies describe the incidence or
prevalence of bipolar disorder in the general population. This is not the same thing as the
frequency with which a practitioner will encounter bipolar disorder in clinical settings.
Bipolar disorder is more common in outpatient settings than in nonreferred community
samples, and bipolar is more frequent in settings providing more intensive services due to
the acuity of the illness. Table 2 lists prevalence rates from multiple settings. The table also
includes information about how the diagnoses were made, whether both parents and youths
were interviewed, and other features that might influence the comparability of the estimates.
Another limitation is that different groups and settings use somewhat different definitions of
bipolar disorder, which also change the rates and their generalizability to other clinical
settings. However, these rates still provide meaningful benchmarks against which clinicians
can compare the rate of their bipolar disorder diagnoses. They also offer some indication of
whether bipolar disorder is likely to be rare or common in a given setting.
Risk Factors
Research has identified multiple risk factors that might pertain to bipolar disorder. Tsuchiya
and colleagues recently reviewed more than 100 studies evaluating more than 30 different
risk factors. They concluded that only a family history of bipolar disorder is the only well-
established risk factor for bipolar disorder that should warrant clinical attention45. In studies
of the offspring of bipolar parents, the risk of developing bipolar disorder appears to be at
least five times higher than in the comparison groups 46, and estimates of the recurrence risk
in adult samples indicate that the lifetime risk may be increased ten-fold 47. A recent review
recommended that clinicians treat a history of bipolar illness in a first degree relative
(biological mother, father, or full sibling) as increasing the risk of developing bipolar
disorder by a factor of 5.0 48,49. Bipolar history in a grandparent, aunt, uncle, or half sibling
would confer half as much risk (e.g., 2.5 times higher) based on the data suggesting that
bipolar is a polygenic illness. These changes in likelihood are large enough to be informative
in clinical assessment. At the same time, they are not so large as to make a diagnosis of
bipolar disorder automatic; in fact, most people with an affected relative will not have
bipolar disorder themselves. Table 3 lists other risk factors for pediatric bipolar disorder.
These risk factors are less well established than family history, but are sufficient to prompt
additional assessment of the possibility of a bipolar diagnosis.
There are several concerns that arise with regard to family history as a risk factor relevant to
diagnosing pediatric bipolar disorder. These include: (a) the fact that the literature cannot yet
disentangle genetic versus shared environmental familial factors, (b) the low diagnostic
accuracy about bipolar diagnoses in general will undermine the sensitivity of family
histories of bipolar disorder, and (c) bipolar disorder has historically been underdiagnosed in
minority groups in the U.S.A., with it often misdiagnosed as schizophrenia or antisocial
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behavior 50,51. For the purposes of formulating a diagnostic impression, it is not necessary to
tease apart genetic versus environmental contributions. The poor sensitivity of family
history means that failure to report a bipolar history cannot be assumed to be accurate,
whereas positive reports of family history may be given greater credibility. The historical
inaccuracy of bipolar diagnoses in minority groups means that clinicians need to inquire
about mood symptoms whenever they hear about other mental health issues in relatives.
Learning about prior treatment history of family members will also provide valuable
information about attitudes towards treatment and adherence, and potentially about
treatment response as well 52.
Combining information: Impressionistic versus actuarial methods
How best can a clinician utilize information such as a positive family history of bipolar
disorder, or test results? Clinical decision making is usually done based on expertise and
impressionistic synthesis of different pieces of information about the individual patient.
Case formulation and diagnosis are highly technical skills that integrate multiple variables
and involve considerable amounts of training. Within a typical assessment framework,
knowledge about the family history becomes one more piece of data to blend into the global
diagnostic impressions, increasing concern about the likelihood of bipolar disorder, yet not
guaranteeing the diagnosis. Family history is a “red flag,” ideally triggering other
assessment procedures and helping build the case for a bipolar diagnosis when other
confirming evidence emerges.
Using a Nomogram to Estimate Probabilities
It also is possible to use information about family history in a more quantitative manner.
Evidence Based Medicine (EBM) advocates the use of Bayesian approaches for assessing
the probability of a patient having a diagnosis 53. Bayesian methods focus on combining
new information with the prior probability of a diagnosis in order to estimate a revised,
posterior probability. Bayesian approaches have been available for centuries, but have not
gained much popularity in clinical settings prior to the EBM movement. There are now a
range of options for practitioners who want to use Bayesian methods. In addition to doing
the computations by hand, there are also applets available on the Web or for personal digital
assistants, and there are also “nomograms” that function like a probability slide rule,
facilitating estimation of probabilities without requiring any computation, as shown in
Figure 1.
Youngstrom and Duax 48 provide a detailed description of how to use a nomogram to
estimate the probability of a youth having bipolar disorder when there is a family history of
the illness. One first determines a starting probability, before considering the other
information that will be synthesized with it. In the absence of any other information, the
base rate of the diagnosis—as contained in Table 2--provides a helpful starting point 54. The
base rate anchors the clinical decision with an objective consideration of whether bipolar
disorder is going to be uncommon or fairly frequent in a clinical setting. The clinician
locates the starting probability on the left-hand scale of the nomogram.
The middle line of the nomogram quantifies the impact of the new piece of assessment data,
quantified as a “diagnostic likelihood ratio” (DLR)53. Conceptually, the DLR indexes the
change in risk of a condition by comparing the rate at which the assessment event (such as a
positive family history, or a high test score) occurs in cases with bipolar disorder to the rate
of occurrence for the same assessment event in cases without bipolar disorder. In other
words, the DLR is the ratio of the sensitivity of the assessment to bipolar disorder (out of
100 cases with bipolar disorder, how many would obtain a positive assessment result),
divided by the false alarm rate (out of 100 cases that do not have bipolar disorder, how
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many would also “falsely” obtain a positive assessment results – the opposite of the tool’s
specificity to the diagnosis). The DLR is the change in the odds of having a bipolar
diagnosis. The nomogram avoids needing to perform calculations to combine the starting
probability with the DLR. Instead, the clinician finds the DLR value on the middle column
of the nomogram, and then connects the dots between the first line (the starting probability)
and the second line (the DLR) and extends the line across to the third, right-hand scale of the
nomogram, which provides the revised probability estimate.
For example, any clinician evaluating a youth coming to an outpatient clinic whose mother
has been diagnosed with bipolar II could use the nomogram in the following manner. First,
the clinician would select the base rate of bipolar disorder, either using local historical
information about the rate of diagnosis at his/her clinic, or by finding a published estimate
from a similar setting. The estimates listed in Table 2 suggested the base rate of 6% for
bipolar spectrum disorders in outpatient clinics. Thus the clinician would put a dot at 6% on
the left-hand line of the nomogram. Diagnosis of a bipolar disorder and a first degree
relative increases the risk of a bipolar diagnosis in the youth by a factor of five to 10. The
clinician opts to use the more conservative estimate, and marks the five on the middle line of
the nomogram. Connecting the two dots and extending the line across the right-hand side of
the nomogram yields aprobability estimate in the vicinity of 24%, indicating that the youth
has approximately a one in four chance of having bipolar disorder. Alternately, this value
can be interpreted as meaning that roughly 24 out of 100 youths presenting to an outpatient
clinic with a family history of bipolar disorder will themselves meet criteria for a bipolar
spectrum diagnosis. If the clinician had picked the more liberal estimate of a tenfold increase
due to family history, then the resulting risk estimate would have been roughly 39%.
Comparing these two estimates illustrates several advantages of using the nomogram (or
other Bayesian methods): (1) combining probabilities and risk factors is not an intuitive or
linear process; (2) it is easy for clinicians to play “what if” scenarios by changing their
starting assumptions or their choice of weight to assign to risk factors --referred to as
“sensitivity analysis” in the EBM literature 53; and (3) the results from the nomogram fall
along a continuum and communicate more accurate information about the degree of
diagnostic certainty. One of the major pitfalls of diagnostic testing is that results are prone to
misinterpretation, especially when test findings are treated as black and white statements
about the patient’s status. The nomogram approach keeps the shades of gray. In this
example, a “black and white” approach to testing would either focus on the test positive
result (family history), or on the posterior probability being below 50%. Focusing only on
the family history, or treating it as if it were synonymous with a bipolar diagnosis in the
child, would be inaccurate in more than 3 out of 4 cases. The alternative would be to
conclude that family history is not diagnostically useful in outpatient settings, because even
when present, most youths will still not have bipolar disorder. Even when conducting a
sensitivity analysis using two different estimates of risk, the results are consistent in
showing that this particular combination of factors put the youth at moderate risk (24-39%)
of having a bipolar spectrum illness. These numbers quantify the earlier statement that
positive family history is a “red flag” that should initiate more comprehensive evaluation of
a possible mood disorder.
How Does the Accuracy of Impressionistic Versus Statistical Methods Compare?
The actuarial/statistical approach to interpreting assessment information is unfamiliar to
most clinicians, and also contrasts sharply with more intuitive approaches to interpretation.
However, the literature is unambiguous that simple statistical approaches, such as the
nomogram method, consistently outperform typical clinical judgment 54,55. The superiority
of statistical approaches has been demonstrated more than 130 times, in disciplines spanning
economics and education as well as clinical decision-making 56. Cognitive science is
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beginning to elucidate reasons why even simple statistical approaches perform better. The
culprits are “heuristics,” cognitive shortcuts that facilitate the rapid identification and
interpretation of information 57,58. These heuristics help the brain process large volumes of
complex information swiftly, but they also lead to systematic and predictable biases. The
human brain pays attention to cues of risk, for example, and to err on the side of high
sensitivity at the expense of false alarms. Though highly adaptive in situations where a
failure to detect risk could result in death, the high sensitivity to risk may lead to
overestimates of rare but risky events in clinical settings 59. A variety of other heuristics
beset clinical judgment, including availability heuristics (such as noticing more bipolar
symptoms in patients after repeatedly hearing about the rise in diagnosis in the popular
press).
Many of these heuristics are likely to be relevant to the clinical diagnosis of bipolar disorder,
suggesting that typical decision-making would be vulnerable to at least as much bias and
error as described in the larger decision-making literature. In fact, emerging evidence
indicates that clinical diagnoses often have low accuracy with regard to bipolar disorder,
including long delays between the emergence and recognition of symptoms 60-62, cyclical
trends where the diagnosis goes in and out of “fashion” compared to schizophrenia 63, low
agreement with systematic research diagnoses of bipolar disorders 64, and large regional
differences in the tendency to diagnose mania or in ratings of severity 65-67. Coding
videotaped interviews revealed a strong tendency for American clinicians to rate manic
symptoms as more severe than British or Asian Indian clinicians 66, and ratings of clinical
vignettes showed that American psychiatrists were more likely to classify ambiguous
clinical presentations as “bipolar” versus the rates identified by British clinicians 65. More
encouragingly, another vignette study has found that people can learn the nomogram
approach quickly, and that applying the nomogram to the same clinical vignette results in
significantly more accurate estimates of bipolar risk, greater consistency and agreement
about the degree of risk (i.e., much smaller range of opinion, and smaller standard
deviations), and a marked reduction in overdiagnosis of bipolar disorder 67. Similar
improvements in decision-making have been documented in numerous other areas of
medicine 53.
Questionnaires and Checklists
Questionnaires and behavior checklists are an important tool in the kit of pediatric
healthcare professionals. They offer an inexpensive, systematic way of gathering
information, potentially from multiple sources (e.g., teachers as well as parents or youths).
The instruments can cover a broad range of areas of functioning and impairment, or they can
drill deeper into more narrowly defined areas, helping to clarify diagnosis or establish the
severity of problems. No single instrument will be equally suited to all of these diverse
applications. What follows is a brief overview of the evidence pertaining to questionnaires
and checklists with regard to pediatric bipolar disorders.
Broadband Checklists
“Broadband” checklists cover a wide range of behavior problems. Both empirically derived
versions (e.g., the Achenbach System of Empirically Based Assessment, including the Child
Behavior Checklist)68 and DSM-oriented versions (e.g., CSI)69 include subscales dealing
with aggressive behavior, depression, anxiety, attention problems, social problems, and
thought disorder or psychotic symptoms. The empirically derived versions also include
superordinate scales that measure more global levels of externalizing and internalizing
problems. Some versions provide scoring algorithms to map onto potential DSM diagnoses
69, and others include age and sex-based norms, comparing the level of behavior problems to
typical levels of functioning for peers. Few of these instruments include a mania scale,
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reflecting the historical fact that most item pools were generated before there was concern
about the possibility of pediatric bipolar disorder. The exceptions still tend to only include
the mania items in the adolescent version 69 or only on the self-report (and not parent or
teacher report) versions (BASC)70.
There are at least three major roles that a broad-band instrument can play in the context of
evaluating PBD: (1) high externalizing scores can trigger further assessment substituting
other procedures for evaluating mania; (2) low scores can substantially reduce the
probability that a case has PBD; and (3) broadband measures provide an inexpensive method
of gauging the range of associated problems and comorbidities frequently seen with PBD.
The CBCL is the most thoroughly investigated measure with regard to PBD, and evidence
consistently shows that youths with PBD show elevated scores on multiple scales, including
the Externalizing Problems broadband score 71,72. However, in spite of PBD elevating
average scores on several scales, from a diagnostic perspective it is the Externalizing
Problems that convey the most information. After controlling for Externalizing scores, no
other scale or combination of scales provides incremental validity 73. Most cases with PBD
will show high Externalizing scores (i.e., they are sensitive to PBD), but high scores are also
associated with many other conditions (i.e., they are not specific to PBD). This sets up an
asymmetry, where low Externalizing scores are often decisive at ruling bipolar disorder out,
but high scores are ambiguous 74. Because of this, high scores should be treated as another
warning sign, leading to deeper investigation of potential bipolar disorder. On the other
hand, low scores will often decrease the risk enough to effectively rule bipolar disorder out,
unless there are several countervailing risk factors and clinical signs. Table 4 provides the
DLRs associated with low, moderate, and high scores on the CBCL as well as the
Achenbach TRF and YSR. More diagnostic information can be wrung from tests by
estimating DLRs for multiple segments corresponding to low, medium, and high scores (as
opposed to the common practice of setting a single threshold)53. The low scores on the
CBCL are more powerful at reducing probability of bipolar (DLR = .04) than extremely
high scores are at increasing risk (DLR = 4, versus a 25 for a low score reducing risk)53.
Finally, regardless of whether the behavior problems represent true comorbid diagnoses,
versus elements of a “core phenotype” of pediatric bipolar disorder or secondary
consequences of the illness, the other clinical syndrome scales on broadband measures
provide valuable information about functioning and other potential targets for treatment. For
example, severe attention problems and chronic hyperactivity often require adjunctive
treatment with stimulants even after mood stabilization has occurred 75-77; and the social
problems associated with PBD also respond well to targeted interventions 78,79.
Mania specific measures
Measures of mania for youths have proliferated over the last decade (see Table 4). They
vary widely in terms of item content, reading level, and degree of validation. Although many
are brief and most are in the public domain, the rarity of PBD and the false positive rates
produced by all of the tests preclude recommending the use of any mania checklist as a core
component of outpatient assessment batteries. However, the best available measures are
markedly more specific to PBD than the broadband instruments, suggesting a cost-effective,
two stage approach to assessment (see Figure 2)49. First, the clinician would gather general
developmental history and family history, which would include an assessment of several risk
factors for PBD. Second, they would give a broadband measure as a way of getting a rapid
scouting report about a wide array of clinical domains. If the family history and
externalizing scores both were low risk, then bipolar disorder is effectively ruled out (Figure
2). If either the family history is significant for bipolar disorder or the Externalizing score is
high, then the clinician would supplement the assessment battery with a mania-specific
measure. At present, the best validated and most discriminating instruments are the PGBI 33
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and its 10 item mania form 80, the Parent MDQ 81,82, and the CMRS 83 and its 10 item form
84. Other instruments have either not performed as well, or they have not been validated
under similarly generalizable clinical circumstances 85. These three instruments produce
functionally interchangeable results in terms of diagnostic assessment. As new papers are
published, test users should compare the instruments not only on their area under the curve
(AUC) in receiver operating characteristic (ROC) analyses (which combines the diagnostic
sensitivity and specificity into a single summary score), but also on the quality of the study,
sample, and reporting 86.
Interpreting Test Scores
The clinician can choose to interpret test scores from rating scales in a number of ways. The
most common method is a categorical, impressionistic interpretation, where scores are
grouped into “high” and “low” ranges. It is also possible to be more formal about the
quantification of risk information conveyed by test results, using the same array of options
as described earlier when interpreting family history. Current thinking in EBM is that the
use of diagnostic likelihood ratios is a preferred strategy 53. The DLR for a test result is the
percentage of cases with bipolar disorder divided by the percentage of nonbipolar cases
scoring in the same range. If a publication provides the sensitivity and specificity, then it is
straightforward to convert these values into a pair of DLRs for scores above and below the
threshold 53. Table 4 includes the DLRs for all available tests with regard to PBD at the time
of writing.
Perusal of the DLR values leads to several observations. Many of the DLRs associated with
low test scores are values lower than 1.0. A DLR of 1.0 indicates that the test result or risk
factor did not change the probability of a bipolar diagnosis, because the score is equally
likely to occur in both bipolar and nonbipolar reference groups. DLRs smaller than 1.0
reflect that the score is much more likely to occur in nonbipolar cases, thus reducing the
likelihood that the current client has bipolar disorder. Whereas a value of 2.0 would signify a
doubling of the odds of a bipolar diagnosis, a value of 0.5 would convey a similar change in
odds in the opposite direction. DLRs greater than 10 or smaller than 0.1 are often decisive
pieces of information 53: They can change a prior probability of 50% (even odds) to more
than 90% or less than 10% posterior probability. These benchmarks lead to the additional
observation that available instruments are more powerful at decreasing the likelihood of
bipolar disorder than at increasing it (i.e., there are many test results yielding DLRs less than
0.1, but few with DLRs greater than 10, and none that have been validated in samples with a
high degree of clinical generalizability). Small DLRs can actually play a valuable role by
reducing the tendency to overdiagnose PBD 1,2,67.
To use these DLRs with a nomogram, one follows the same procedure as described with the
interpretation of family history, only using the test score’s DLR as the estimate on the
middle line of the nomogram 87. When multiple DLRs are available, such as when both
family history information and a CBCL Externalizing score are available, then all pieces of
information can be combined within the nomogram framework. The sequence does not
matter. Family history could be considered first, or the test score; or the DLRs could be
multiplied together and the product used instead during a single pass through the nomogram.
Algebraically, these are all equivalent scenarios. This degree of flexibility is extremely
valuable clinically, though, as often it will not be possible to obtain some pieces of
assessment information for a specific case, and the order with which clinical data become
available often varies across cases. In contrast, other actuarial methods such as lookup
tables, logistic regression, or decision trees require that all the component variables be
measured for each case, and that they be applied in a specified combination or sequence .
Building on the earlier example, if a very high CBCL Externalizing score (T= 83) was added
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to the case with a positive family history of bipolar disorder, then the current probability
(24% for based on a first degree relative increasing the risk of a bipolar diagnosis by a factor
of 5) would be entered on the lefthand line of the nomogram. Table 4 provides the DLR
associated with the T-score (DLR = 4.3 for an adolescent scoring this high on the CBCL).
Combining the prior probability and the DLR algebraically yields an estimate of 58%. Using
the nomogram adds some imprecision, both because reference points need to be visually
interpolated, and because of error connecting the dots; but clinical estimates using the
nomogram still wind up being centered around the best estimate and are dramatically more
precise than when clinicians interpret the same information impressionistically67.
Either a high score on a broadband measure or a positive family history of bipolar disorder
would justify the addition of one of the more specific mania scales to the assessment
process. However, when the same person fills out two rating scales, only one of them should
be incorporated into the formal assessment process, whether it be the nomogram or another
method of combining risks 14. The scores on the questionnaires will be highly correlated
with each other by virtue of coming from the same source, and thus will yield redundant
information. Treating multiple questionnaire scores as if each was introducing new
information will create bias in the probability estimates. The bias can be substantial when
the scores are highly correlated (r > .5), which will often be the case when the same person
fills out multiple instruments, even when they measure different constructs 88. As a result,
the clinician should take the most valid piece of information available from the informant
and substitute it into the nomogram cycle, ignoring other scores from the same source 14. In
our case example, the high CBCL score would cause the clinician to ask the caregiver to
complete the Parent GBI. A very high score on this tool (e.g., a raw score of 51; see Table 4)
has a DLR of 9.2. This would replace the DLR of 4.3 from the CBCL completed by the
same caregiver. Combining the DLR of 9.2 with a prior probability of 24% (based on the
family history and the base rate of PBD in outpatient settings) generates an estimate of 58%
risk.
Permuting the possible combinations of DLRs from the combination of family histories and
test scores yields a range of 8 to 24 probability estimates per test. When also accounting for
the differences in base rate across clinical settings, the number of distinct probabilities will
exceed 100 for each test x family history x setting combination. This reveals another
advantage of the nomogram approach compared to generating tables of estimates for each
configuration, or versus trying to weight the information sources intuitively. The tandem of
family history and rating scales is powerful enough to move the probability estimate of a
PBD diagnosis to less than 1% (no family history plus a low score on a broadband) or as
high as 85% (using a more aggressive estimate of 10-fold increase in risk due to family
history, plus a very high score on a PGBI or comparable tool). Thus, an evidence-based
approach to assessment can rule PBD out in many cases, and reduce the tendency to
overdiagnose bipolar disorder; but even high risk combinations are not sufficiently accurate
for diagnosis of bipolar disorder to replace a careful symptom level assessment of bipolar
disorder.
Cross Informant Issues
There has been a substantial amount of research on the validity of youth self report and
teacher report as well as caregiver report (almost always mothers) about bipolar disorder.
Findings consistently show the greatest validity for parent report, which shows significantly
larger effect sizes than youth or teacher report in all published studies where the same
instrument is available from multiple informants 73,82,89,90. Examining Table 4 reveals that
the DLRs for parent report are consistently larger than the DLRs for youth or teacher report
on the same instruments. The greater validity of parent report persists even when the parent
has a diagnosed mood disorder 91.
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That parent report outperforms self-report contradicts conventional wisdom that self-report
is a better source of information about mood disorders 92. The lower validity of youth report
appears to be due to a combination of mania compromising insight into one’s own behaviors
93 and manic symptoms tending to disturb others before the affected individual perceives
them as problematic 94. The low validity of teacher report persists even when teachers
complete mania-specific rating scales 95. Of note, the agreement between parents and youths
or parents and teachers is actually significantly higher than typical for cross-informant
agreement 91,96, and youths and teachers report significantly more behavior problems in
PBD cases than would be predicted based on the parent’s level of concern alone 91. The
challenge is the difficulty of intuitively appreciating what a cross-situational correlation of .2
or .3 might look like at a case level, so instances where dyadic agreement is actually good
are often misinterpreted as one person having exaggerated concerns. Clinicians will often
encounter families where the parent reports more mood issues than the teacher or youth. The
evidence-based approach to these discrepancies is not to automatically discount the parent
report, but rather to systematically gather additional information to evaluate the possibility
of PBD 14. At a statistical level, youth and teacher report provide only modest –and often
insignificant—incremental validity after controlling for parent report 73,94. However, the
correlation between parents and youths or teachers is sufficiently low that these can be
treated as functionally separate sources of information and combined within the nomogram
framework. Evidence also suggests that cases where mood symptoms are noticeable across
informants and settings may have greater impairment 97, also justifying the effort required to
collect multiple perspectives. Teacher report can add useful information about the degree of
problems in the school setting 95, and youth report adds data about the degree of insight into
problems and motivation for treatment, both providing helpful prescriptive information to
guide intervention.
Deciding to Intervene: Crossing the Treatment Threshold
The clinical process has three different options with regard to diagnosis: Ruled out,
sufficiently well-established that treatment for the condition should begin, or else possible
but not established. In EBM, the probability of diagnosis theoretically ranges from 0 to
100%, and there are two thresholds that separate the three different clinical options (see
Figure 2) 53. The Test-Wait threshold separates the low risk zone - diagnosis is effectively
ruled out - from the indeterminate middle range. The Test-Treat threshold demarcates the
zone where probability is high enough to initiate treatment. Figure 2 does not specify
probability levels for these thresholds. In practice, the location of the threshold should take
into consideration the risks and benefits associated with treatment, as well as patient
preferences. There is a formal framework for collecting and incorporating these utilities into
adjusted thresholds 98, with perhaps the easiest approach described in an EBM handbook 53.
As diagrammed in Figure 2, the combination of family history and questionnaire data will be
sufficient to rule bipolar disorder out when both indicate low risk. High risk cases, with
positive family history and high scores on mania measures, will still fall below the Test-
Treat threshold – especially when considering the stigma, treatment burden, and potential
side effects attendant to recommended treatments for PBD 99. Within an EBM framework,
probabilities falling between the Treat and Wait thresholds indicate the need for continued
assessment. New assessment data then gets combined with the current probability until the
revised probability crosses the Wait threshold (ruling the diagnosis out) or the Treat
threshold (ruling the diagnosis in).
Doses of Treatment Model
Psychology has long had a model of “levels of intervention,” where primary preventions
might be offered to everyone in order to avoid onset of an illness, secondary interventions
might be offered only to targeted high-risk groups, and tertiary interventions would
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deployed for cases already manifesting a disorder 100. Preventive measures need to be low-
risk and low cost if they are going to be applied widely regardless of risk. Tertiary
interventions can be higher risk and expense because they have been reserved for cases with
established diagnoses. This “levels of intervention” model can be mapped onto the EBM
diagnostic threshold model 15, as shown in Figure 2, right-hand side. Synthesizing these two
models creates a set of assessment and treatment recommendations for each of the three
ranges of probability for a bipolar diagnosis. Instead of labeling cases having mid-range
probabilities as “indeterminate,” they can be called “moderate risk” and treatment using
low-risk methods can start. Techniques such as psychotherapy, dietary supplementation, and
improved sleep hygiene all might be tried for cases in this range. So long as the burden,
risks, and costs are low, then treatments that are nonspecific or potentially preventative can
be used, even while assessment continues and clarifies diagnostic impressions.
Leaving Limbo: Ruling Bipolar Disorder In or Out
Even when multiple risk factors are present, a clinician cannot assume that a PBD diagnosis
has been established. How best should they proceed? The following suggestions provide an
overview of strategies that help to confirm the diagnosis in high risk cases, or to rule a
bipolar diagnosis in or out for cases that fall in the intermediate range of risk.
Diagnostic Interviews
Diagnostic interviews remain the standard of practice for determining clinical diagnosis. The
typical unstructured diagnostic interview is prone to a variety of heuristics that render its
reliability quite low 101. For PBD, circumstances are likely to worsen the already typically
poor degree of inter-rater, due to issues such as the lack of formal training in recognition of
PBD, the usage of different operational definitions, and the controversy around the
diagnosis. Structured diagnostic interviews avoid some of the shortcomings of informal
interviews, including systematic coverage of relevant symptoms and formal algorithms to
make DSM diagnoses 101. However, most structured interviews were designed before PBD
was considered a serious possibility in youths, with the consequence that many pediatric
structured interviews do not include a mania module, and those that do might include few if
any modifications to the probes or anchors to facilitate recognition in pediatric cases 14.
For this reason, semi-structured diagnostic interviews such as the KSADS have become the
accepted standard for PBD research 102. Different versions of the KSADS have
demonstrated good reliability and validity with regard to PBD 103,104. There are some
obstacles hindering the widespread clinical adoption of semi-structured interviews. These
include the necessity for extensive training, or else the semi-structured aspect opens the door
for differences in clinical judgment to undermine the reliability 66, as well as the substantial
amount of time required to administer and score the interview. A full KSADS can take
anywhere from 2 to 8 hours to complete with a family, with administrations by experienced
clinicians often averaging around 3 hours for typical cases. However, more streamlined
versions of semi-structured interviews deserve serious consideration as a potential
component of clinical assessment 105. The emerging literature around clinical diagnosis of
PBD suggests that there may be great need for semi-structured approaches despite the
increased expense and burden involved. Medicaid and other providers will often reimburse
for the diagnostic assessment time if medical necessity has been demonstrated. The
framework described here – starting with a combination of rating scales and family history -
provides strong documentation of medical necessity for such additional evaluation.
Clinicians who want to adopt semi-structured interviews as part of their assessment portfolio
should pick an instrument that covers manic and depressive symptoms thoroughly, includes
developmentally appropriate anchors, and supports the diagnosis of “spectrum” conditions
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(such as bipolar II, cyclothymic disorder, and bipolar NOS), as these will be more common
than bipolar I, yet impairing enough to represent major clinical concerns.
“Handle” Symptoms
Not all symptoms carry equal weight towards making a diagnosis of mania. The DSM-IV
and ICD criteria give greater emphasis to elated mood instead of irritable mood. Elated
mood requires only three additional symptoms to support a diagnosis of mania, versus four
additional symptoms for irritable mood 17. This policy acknowledges that elated mood has
greater diagnostic specificity to mania, whereas irritable mood is diagnostically nonspecific.
Research suggests that decreased need for sleep, unstable self esteem and grandiosity,
hypersexuality, racing thoughts, and psychotic symptoms are all relatively specific to PBD 7.
The sensitivity of each of these symptoms is low enough that none should be required for
making a diagnosis of bipolar disorder, or else somewhere between a quarter and two thirds
of bipolar cases might be excluded 7. Each of these symptoms is also liable to occur in at
least one other condition likely to be encountered in many clinical settings. For example,
hypersexuality can be a sign of sexual abuse, and inflated self-esteem is frequently seen in
conduct disorder 7. However, a clinician can learn how these symptoms often manifest in the
context of PBD 106, and careful probing around these symptoms is an important component
of refining diagnostic impressions. Evidence that any of the possible manic symptoms occur
episodically, as opposed to chronically, or that they fluctuate with changes in mood and
energy, heighten the suspicion that they are due to a mood disorder rather than a more
chronic condition such as ADHD 107. If the symptom occurs with an unusual Frequency, if
the Intensity is excessive, if the Number of occurrences within an episode is extreme, or if
the Duration is exceptional compared to age appropriate behavior, that also helps build the
case in favor of a mood diagnosis99,108.
Extending the Window of Assessment
Another crucial strategy to improve the detection of PBD is to extend the window of
assessment beyond the conventional single session of intake assessment 49. Relying on a
single panel of information focused on the presenting problem will rarely be enough to
allow a firm diagnosis of PBD.
Developmental History
Gathering a developmental history is a routine component of pediatric assessment. Its role is
especially helpful when evaluating the possibility of PBD. In addition to gathering data
about the family psychiatric history, pre- and perinatal risk factors and complications and
temperamental characteristics all deserve consideration 108. Developmental trajectories can
help distinguish between chronic conditions such as ADHD (which is formally required to
have onset before age seven) versus episodic mood presentations 107. Even though not all
authorities concur that PBD will always have an episodic presentation, identifying episodic
presentations still carries treatment utility by suggesting different intervention strategies
52,109. The most intensive form of retrospective information gathering would be to complete
a retrospective life chart 110. The retrospective life chart is a tool that asks the family to
reconstruct a week-by-week summary of the youth’s past mood and energy levels, using a
variety of anchors and techniques to facilitate accurate recall. The retrospective life chart
can yield valuable information about the chronicity versus episodicity of mood presentation,
and it can help to identify triggering events. However, the time and effort involved is
substantial, and retrospective memory is subject to several sources of bias. Clinically, the
costs and possible benefits need to be balanced on an individual case basis before adding a
prospective life chart.
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Extending the Assessment Window Forward
The other way of moving beyond a single-session intake is by extending the window of
assessment forward in time. There are many means of accomplishing this. They include
starting with a diagnosis of “rule out bipolar disorder” based on the initial intake, and
following up with additional assessment to clarify the diagnosis. The EBM threshold model
operationalizes this concept by indicating continued assessment for as long as the
probability of PBD falls between the Wait and Treat thresholds 53.
Another approach is to shift to a “dental model” of assessment, where ongoing “checkups”
are scheduled to gauge mood and energy over the course of treatment 49. At a minimum,
these could consist of asking the patient at each visit about their mood and energy since the
last visit. Alternately, the family could complete brief rating scales every few weeks over the
course of treatment 76,77. The clinician could also quantify impressions using ratings such as
the Children’s Global Assessment Scale (CGAS)111. At the most intensive, the clinician
could suggest doing prospective life charting 110. In a prospective format, the patient records
changes in mood and energy on a daily basis, and also notes any coinciding events. There
are free prospective life charts for use with youths available on the web (Google “bipolar life
chart” to find numerous examples), and sophisticated online versions are now available. If
the family is willing and able to complete prospective life charts, then the information is
highly useful for refining diagnosis and guiding treatment; but the demands of life charting
exceed the resources and motivation of many families. The informal “mood and energy
checkup” at each visit represents the minimum level of prospective information gathering
that should be routine when working with mood disorders.
Measuring Severity
In addition to guiding diagnosis, a second crucial role of assessment tools is quantifying the
severity of mood problems. More acute mood disturbance will require a different level of
intervention services, with inpatient hospitalization providing the most intensive treatment
for severest mood disturbance. Besides navigating the selection of treatment setting, the
severity of the mood problems will help prescribe different treatment options. More severe
mood problems will suggest the use of pharmacotherapy as a first line treatment, and
combination treatments with both psychotherapy and one or more pharmacological agents
may be needed to stabilize mood 99. Moderate levels of mood symptoms may result in lower
dose interventions, including outpatient psychotherapy with longer intervals between
sessions, or less aggressive dosing of medications. Assessments of severity are also crucial
for establishing benchmarks against which to measure treatment response.
Clinician Ratings
Clinical ratings of the severity of mood problems steer the treatment of PBD. Typically the
assessment is informal, with all of the attendant limitations described in the discussion of
informal diagnosis 101. There are global rating scales, such as the Global Assessment of
Functioning 17, the CGAS 111 and the Clinician Global Impressions scale (CGI) 112, that
assign a number to the clinician’s overall impression of functioning. There also is a bipolar
version of the CGI, where the clinician rates manic and depressive symptoms separately 76.
The next level of sophistication would be to use a semi-structured clinical rating scale. The
two most widely used in research with PBD are the Young Mania Rating Scale (YMRS)113
and the Children’s Depression Rating Scale-Revised (CDRS-R) 114. Both have shown
evidence of good reliability and acceptable validity in pediatric samples 115-117. This is
reassuring for the YMRS, which was not originally designed for use with children or as an
interview 113. The YMRS and CDRS-R both omit symptoms that are DSM-IV criteria for
mania or depression, and they omit other associated features that can be important in
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assessing the severity of mood disturbance 14. The YMRS does not include a grandiosity
item, for example; nor does it measure threat of harm to self. There are newer rating scales
designed specifically for use with children and adolescents, that provide more
developmentally appropriate anchors, use consistent ratings across all items, and include all
DSM symptoms of mood episodes. The KSADS-Mania Rating Scale and Depression Rating
Scales have all of these refinements and show good psychometrics 118. Clinicians
contemplating the use of mood rating scales should be aware that the interviews require a
moderate amount of time (typically 15 to 45 minutes), and the semi-structured format is both
a blessing and a bane in terms of often leading to sizeable differences in scoring of the same
interview by different clinicians 66.
Checklists: A Reprise
Checklists can complement clinician ratings in measuring severity. Checklists are
inexpensive, require virtually no training to use, and incorporate no little or no clinical
judgment in scoring; they are the mirror-image of clinician ratings in each of these regards.
Checklists also afford the assessment of a broader range of symptom domains than can
generally be accomplished via clinician ratings. Parent checklists, in particular, have
demonstrated a strong correlation with clinician-rated measures of severity, and they also
show good sensitivity to treatment effects 76,77.
Quality of Life
There is growing emphasis on quality of life as a vital aspect of the burden of illness and
successful outcome of treatment. Several rating scales have been used to measure quality of
life in the context of PBD 119,120. The KINDL is especially attractive for clinical use
because it has two parent and three youth report versions that are developmentally staged,
and because it can be used free of charge (http://www.kindl.org/indexE.html).
Process Measures to Use During Treatment
Many of the assessment tools discussed above can contribute to process measurement during
treatment. Prospective life charts, in-session mood and energy checkups, or repeated
administrations of brief rating scales can chart response over the course of intervention. Of
the various checklists available, the 10-item versions are generally preferable for repeated
administration due to the reduced burden. An exception is the MDQ 81: Although it is a
good diagnostic aid, it does not capture information about the severity of current mood
problems, so it is not useful as a process or outcome measure.
Prospective life charts also can provide similar information to the three-column and five-
column charts used in cognitive behavioral therapy 121. All of these assessment devices ask
the patient to chart fluctuations in mood as well as associated events. The three-column chart
asks the patient to then also write down what they were thinking at the time, linking the
cognition to the emotional response; and the five-column chart goes further by adding an
alternative cognition and the emotional response it generates 121,122. For those families that
are able to do prospective life charting, it is possible to seamlessly weave the components of
three- and five-column charting into the recording and in-session discussions of the data.
Other aspects of treatment process that are important to assess include adherence, risk of
harm to self and others, and side effects. Measures of adherence can include regularity of
kept appointments, completion rates of homework assignments, and compliance with
prescribed dosing regimens. Because mood disorder is a major risk factor for suicide and
self harm, it is crucial to regularly assess potential suicidal ideation, as well as the presence
of a plan and means 8. Similarly, the degree of aggression and irritability that often manifest
with PBD require regular, documented assessment of risk to others. Finally, the potential
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side effects for pharmacological treatments are both numerous and potentially quite serious,
so they need careful patient education and ongoing monitoring 123. Although there are
published rating scales for each of these domains, in general they are sufficiently
cumbersome that it will usually be more practical to accomplish these goals via direct
assessment by the clinician. At the same time, the clinician must follow through on
assessing each of these domains and not fall into the trap of irregular assessment and poor
documentation.
Measuring Outcomes
Many of the same questionnaires, checklists, and clinician rating scales used to evaluate
severity also can provide good measures of outcome. The tools best suited for outcome
assessment have good reliability, good content coverage of the relevant symptoms and key
aspects of functioning, and are sensitive to treatment effects. Content that is useful for
diagnosis may not be identical to the content most useful for outcome measures. For
example, irritable mood is ambiguous when used for diagnostic purposes, but irritability is
one of the most distressing and impairing features of PBD, and so it definitely merits a
central role in outcome assessment. Conversely, two of the eleven items on the YMRS show
weak validity when applied to pediatric cases (lack of insight, and bizarre appearance)117,
and their inclusion probably dilutes the sensitivity of the YMRS to treatment effects. From a
psychometric perspective, outcome measures can and should be longer than the process
measures administered more frequently during treatment. The greater length improves
reliability and thus the potential validity of the outcome measure 124, and the length is more
likely to be tolerable if administered infrequently. Counter intuitively, statistical power to
detect change can be increased by shifting more items to the post-test instead of the pre-test
125. Clinicians could take advantage of this by using more lengthy outcome measures as part
of the termination assessment, where families would not also be spending substantial
amounts of time on diagnostic evaluations or administrative paperwork (such as insurance
forms). Of the available instruments, the CBCL and the Parent and Adolescent GBI have the
most established track record as outcome measures. The CMRS also appears promising. Of
the clinician rating scales, the YMRS and CDRS have by far the largest data base in the
literature, but the KSADS MRS and DRS deserve consideration due to their advantages in
terms of content coverage and developmental appropriateness.
Definitions of Response, Remission, and Clinically Significant Change
In psychiatry outcome studies, treatment response has most commonly been defined using
thresholds for percentage reductions in the severity of mood symptoms. For example, a 33%
or 50% reduction in YMRS scores from baseline might define “response” to treatment
126,127. Such definitions of response are convenient, but they also have some major
shortcomings. These limitations include (a) the fact that different patients will need to show
varying amounts of change to qualify as a responder, depending upon their initial level of
severity; (b) the fact that mania and depression often show different responses to treatment,
and sometimes one might worsen at the same time that the other mood symptoms are
improving; (c) percentage reductions in symptoms do not necessarily translate into
syndromal remission or improvements compared to normative benchmarks; and (d)
percentage reductions ignore the degree of precision of an instrument, potentially penalizing
more accurate instruments because they are more reliable. The vulnerability of definitions of
“treatment response” to unreliability could be a factor contributing to the high rates of
placebo response observed in clinical trials.
Multiple refinements have been developed to address these shortcomings of the percentage
change approach. These include comparisons to “rules of thumb” about thresholds for
mania, hypomania, or depression; the empirical definition of thresholds that distinguish
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responders from nonresponders 128; the use of compound definitions of remission that
integrate improvement on mania and depression simultaneously 76; and the articulation of
formal clinical definitions of remission and recurrence 129. None of these has achieved clear
dominance in the research arena, and few have permeated into clinical practice yet.
Perhaps the most fully articulated framework for evaluating outcomes is the “clinically
significant change” model proposed by Jacobson and colleagues 130. Their definition of
clinical significant change requires achieving two goals: Demonstrating reliable
improvement given the psychometric precision of the outcome measure, and also passing
one of three normative benchmarks defined by the range of scores observed in clinical and
nonclinical reference samples. Reliable change is tied to the standard error of the difference
score, which is a direct measure of the instrument’s precision at measuring change. Jacobson
advocated dividing the patient’s raw change score by the standard error of the difference 130.
This would standardize the change score, converting it to a z-score (with a mean of zero and
standard deviation of one, the same metric as the familiar Cohen’s d effect size). Jacobson
called this standardized change score the “Reliable Change Index” (RCI). Two advantages
of calculating the RCI are (a) that it facilitates comparison of the magnitude of treatment
response across different measures (e.g., a 5 point reduction in the YMRS does not mean the
same thing as a 5 point reduction in a CDRS-R score; but converting both to RCIs would
make clear whether the patient’s mania or depression was responding more to treatment);
and (b) that RCIs can be compared to established benchmarks drawn from the normal
distribution. RCIs larger than 1.65 are big enough to be 90% certain that the patient is
responding, and RCIs larger than 1.96 are enough to be 95% confident. Three drawbacks of
the RCI are (a) that it is unfamiliar to most clinicians, (b) it involves computation, and (c) it
requires knowledge of the standard error of the difference for the test, which is rarely
available. However, all of these problems are tractable. A recent chapter presents the
standard error of the difference for several commonly used outcome measures relevant to
PBD 14. Table 5 also includes “critical values” expressed in the raw or T-score metric that
clinicians normally use, as a way of bypassing any computation. For example, if a patient
shows at least 10 points of improvement on the YMRS, or 6 points on the CBCL
Externalizing, then the clinician can be 90% sure that they are changing in this domain (or
95% sure that the patient is improving, one-tailed).
The second part of the definition of clinically significant change entails demarcating
benchmarks based on reference clinical and nonclinical samples. Jacobsen defined three
benchmarks, called simply A, B, and C. Youngstrom has suggested referring to them as
Away from the clinical range, Back into the normal range, and Closer to the nonclinical than
clinical mean14. The Away threshold is set at two standard deviations below the mean for a
clinical sample on the measure 130. For PBD, estimating the Away threshold would involve
finding a sample of youths with PBD and then locating the score on the instrument that fell
two standard deviations below the sample mean (roughly corresponding to the 2.5th
percentile for cases with PBD). Similarly, the Back into the nonclinical range is established
by finding the score that falls two standard deviations above the mean for a nonclinical
comparison group. The Closer threshold is found by estimating the weighted mean of the
clinical and comparison means, weighting by the sample standard deviations. The technical
manuals for many tests include the needed information to calculate the three thresholds, and
Cooperberg 131 calculated the thresholds for several other measures pertinent to PBD. Table
5 includes the thresholds for several commonly used outcome measures.
Clinically significant change is frequently used to evaluate individual response in
psychotherapy trials. It is a stringent definition of response, and it tends to produce lower
estimates of response rates than the simple percentage symptom reduction approach 132. The
conservative definition should cause celebration when actually achieving any of the
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definitions of clinically significant change. Studying Table 5 also reveals that some
definitions are impossible given the distributional characteristics of a measure. The Away
threshold frequently would require obtaining negative scores, because the clinical mean falls
within two standard deviations of the lowest possible score on the measure. Similarly, the
Back definition would accept high scores (e.g., T-scores of 70 on Externalizing or
Internalizing problems) as potentially reflecting clinically significant change. This might
make sense when coupled with Reliable Change – a seven point reduction in Internalizing
Problems from a 76 to a 69 could constitute a substantial improvement, for example. Even
so, the thresholds identified by the Closer definition will often provide the most meaningful
benchmarks for outcome evaluation 14.
In summary, outcome evaluation is usually done informally, if at all 101. However, a variety
of assessment tools and definitions of outcome are now available for clinicians working with
PBD. Using formal outcome assessment will help better gauge treatment response and
enable comparisons between clinical practice and the outcomes described in the literature.
The clinically significant change model addresses many of the technical shortcomings of
other outcome definitions, and it can now be used with many –but not all—outcome
measures relevant to PBD. The necessary benchmarks are not available for the CMRS or
KSADS-MRS, for example. On the other hand, all of the different definitions could be
applied to commonly used broadband and public domain measures of mania and depression
using the information contained in Table 5.
Assessment Tools for Maintenance and Relapse Prevention
Longitudinal data indicate that PBD tends to show a recurrent course 10,11, similar to the
high rates of relapse observed in adult samples 8,20. As treatment progresses, an important
component will be planning strategies for monitoring against relapse. Reviewing the life
charts and three- or five-column charts would expedite making a list of events likely to
trigger exacerbation of mood. There are also normative developmental transitions that are
likely to elicit major changes in mood, including the onset of puberty, leaving home, and
major role changes such as graduating or failing out of school. Although not all events can
be anticipated, many can; and a simple assessment strategy would be to list the likely events
and then plan for ways of evaluating mood status when the events arise.
The later phases of treatment can also be a good time to identify warning signs of relapse, or
“roughening” of mood 133. It is helpful to have manic symptoms under control in order to
increase insight into the illness. It also is desirable to have some experience working
together with the patient, as many of the cues of relapse are not diagnostic symptoms per se,
but rather idiosyncratic aspects of the person’s functioning 134,135. A major goal would be to
develop warning signs that the patient would use and trust even when getting hypomanic,
with the attendant feelings of wellness and loss of insight. An example would be how
psychoeducation interventions often help the client learn to use the family or a trusted
roommate as a “watchdog” that helps monitor mood 136.
Given the geographic mobility of both patients and clinicians, a third assessment strategy
worth considering is preparing a “care package” for the next clinician as part of the
maintenance planning. This care package could be based on a review of the components of
treatment, with the patient and practitioner candidly evaluating which were helpful and
which were not. Preparing a list of medications tried and responses or adverse events, and a
list of therapeutic or lifestyle manipulations and their perceived effectiveness would avoid a
lot of guesswork and missteps when resuming active treatment in the aftermath of relapse.
Patients and practitioners could keep copies of the documentation to increase the chances
that it would be available when needed.
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A great deal of research is investigating methods that could soon contribute to the diagnostic
assessment of PBD. Some of the most exciting research includes neurocognitive testing,
functional imaging techniques, and genetic testing. In spite of the promise, expert consensus
is that none of these methods are currently ready for clinical use. Recent reviews of
neurocognitive tests 137 and neuroimaging 138,139 have found that the replicated patterns of
functioning in PBD tend not to be specific to bipolar disorder, but instead overlap with
patterns of functioning seen in ADHD, schizophrenia, and other conditions.
Similarly, the present evidence indicates that bipolar disorder is a polygenic condition, with
multiple genes each contributing small increases in the risk of developing the disorder 140.
However, several companies now are marketing direct-to-consumer genetic testing,
purportedly including tests for bipolar disorder (e.g., https://psynomics.com/). This has
provoked strong criticism from the academic community, arguing that it is premature to
market tests for bipolar disorder and that the results are highly prone to misinterpretation
141. The opportunity for misunderstanding is greatest when the results of any of these new
methods are treated as yes/no, positive or negative tests for bipolar disorder. This review has
demonstrated that although family history, questionnaires, and rating scales are also
imperfect measures, once their biases and limitations become known, it is still possible to
assimilate them into an evidence-based framework for assessment.
Conclusion
The diagnosis of pediatric bipolar disorder remains controversial in clinical practice.
Evidence suggests that it is often diagnosed when not present, and yet many cases of bipolar
disorder are also missed. Despite the aura of controversy, there is considerable consensus
among experts about the validity of DSM-IV based diagnoses in youth. Marked progress has
also been made in validating and honing assessment strategies for PBD. As this review
reveals, it is possible to use the literature to inform choices of assessment techniques that
contribute to diagnosis, treatment selection, monitoring progress, evaluating outcomes, and
long term monitoring and relapse prevention. The review also synthesizes the available
literature with the clinical decision-making framework advocated in Evidence Based
Medicine and in the clinically significant change literature in psychotherapy research. Both
of these frameworks emphasize decision-making about individuals, rather than groups of
patients. In consequence, these models speak much more directly to individual clinical care
than past research typically has done.
There is no aspect of the assessment of PBD that has been “perfected.” Every assessment
tool could be bettered, and each technique offers room for improvement. At the same time,
the number of tools and ideas now available for clinicians to apply immediately in their
clinical practice is impressively large and diverse. The potential gains from employing
evidence based strategies are only hinted at except for in the arena of diagnosis, where
recent studies suggest that the contributions could be huge. The goal of clinical research is to
answer gaps and uncertainties in clinical practice, and research in PBD is poised to support
rapid advances in clinical assessment.
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Nomogram for combining probability with likelihood ratios.
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Flow chart for assessment and treatment thresholds
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Table 2
Base rates of pediatric bipolar disorder in different settings.
Setting Base Rate Demography Diagnostic Method
General Outpatient Practice 2 1% All of U.S.A.
National Ambulatory Medical Care
Survey
High school epidemiological 44 0.6% Northwestern USA high school KSADS-PL y
Community nonreferred 142 1.4% Upstate New York




United States General Population CIDI
United States Child/Adolescent
(Lahey et al., unpublished MECA) 8
1.8% Eastern United States DISC p, y
Community Mental Health Center 23 6%
Midwestern Urban, 80% non-
white,
low-income
Clinical interview & treatment p, y
General Outpatient Clinic 143 6.3% Urban academic research centers WASH-U-KSADS p, y
County Wards (DCFS) 144 11% State of Illinois Clinical interview & treatment y
Specialty Outpatient Service 145 15% to 17% New England KSADS-E p, y (only p young)
Incarcerated Adolescents 146 2% Midwestern Urban DISC y
Incarcerated Adolescents 147 22% Texas DISC y
Acute psychiatric hospitalizations in
1996 – 2004 – children 1
26% All of U.S.A. Centers for Disease Control survey ofdischarge diagnoses
Inpatient Service 97
30% manic symptoms,
<2% strict BP 1 New York City Metro Region DICA; KSADS 
p, y
Acute psychiatric hospitalizations in
1996 – 2004 – adolescents 1
34% All of U.S.A. Centers for Disease Control survey ofdischarge diagnoses
p
Parent interviewed as component of diagnostic assessment;
y
Youth interviewed as part of diagnostic assessment.
Note. KSADS = Kiddie Schedule for Affective Disorders and Schizophrenia, PL = Present and Lifetime version, WASH-U = Washington
University version, -E = Epidemiological version of the KSADS; DSIC = Diagnostic Interview Schedule for Children; DICA = Diagnostic
Interview for Children and Adolescents;
CIDI = World Health Organization’s Composite International Diagnostic Interview. Table modified from Table 1 in Youngstrom (2007) 14.
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Table 3
Clinical interview red flags that should trigger thorough evaluation of possible PBD.
Red Flag Description Reason
Family history of BP* PBD most likely genetically driven 5x – 10x increase for 1st degree
relative; 2.5x-5x for 2nd degree
relative; 2x for “fuzzy” BP in
relative 47,49
Antidepressant Coincident Mania Manic symptoms while being treated
with antidepressants
Undiagnosed PBD 38
Episodic Mood Lability Rapid switching between depressive
and manic symptoms; depressive and
manic symptoms at the same time
Common presentation;
episodicity more suggestive of
mood diagnosis 7
Early Onset Depression Onset < 25 years First clinical episode is often
depression; substantial portion of
pediatric depressions ultimately
show bipolar course 28,148
Psychotic features True delusions/hallucinations in the
context of mood
Delusions/Hallucinations
common during mood episode
40,149
Episodic Aggressive behavior Episodic; high-energy. Not
instrumental or planned; reactive
Not specific, but common 7,40
*
This is the risk factor that is currently most amenable to incorporation in actuarial or Bayesian methods.
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Table 4
Areas Under the Curve (AUCs) and Likelihood Ratios for Potential Screening Measures for PBD
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occurring and at least
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Adolescent Young Mania Rating
Scale -- Questionnaire 82




Children (5 to 10 years)
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.72 (N=141) 82 -- High

















Note: Uses 0 to 4, 0
to 8 scoring (Young
et al., 1978)













Combined Samples (Child &
Adolescent Not Reported
Separately)









Two Item Screen 155 .85 (N=264) 155
.70 (N=500) 85













































Child Bipolar Questionnaire 156 Not reported
(N=135) 157
7.1 Low
Note: All studies used some version of KSADS interview by a trained rater combined with review by a clinician to establish consensus diagnosis.
Diagnostic Likelihood Ratio (DLR) refers to the change in probability associated with the test score. Likelihood ratios of 1 indicate that the test
result did not change impressions. DLRs larger than 10 or smaller than .10 are frequently clinically decisive; 5 or .2 are helpful, and between 2.0
and .5 are small enough that they rarely result in clinically meaningful changes of formulation 158. Generalizability was rated Low, Moderate,
High. Low generalizability meant that the sample was highly selected (e.g., PBD, ADHD, healthy control). Moderate generalizability meant the
sample was less highly selected (e.g., few exclusion criteria). High generalizability meant that the sample did not exclude (e.g., took everyone to
the clinic).
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